Pair Name	10-Gingerol, Paclitaxel
Partner Name	Paclitaxel
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Down-regulation	Expression	ADRB2	hsa154
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	MAPK1	hsa5594
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	SUM159PT	Breast pleomorphic carcinoma	Homo sapiens (Human)	CVCL_5423
In Vivo Model	Human MDA-MB-231 cells (cell density: 5×10⁶ / 200 μL PBS) were injected into the breast fat pad of each mouse.
Result	This data suggests that 10-G may be used as a new chemotherapeutic synergist in combination with paclitaxel to enhance anticancer activity. The potential value of ADRB2 as a target for improving chemotherapy sensitivity was also emphasized.

Pair Name	10-Gingerol, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Inhibition-->Cell metastasis
Gene Regulation	Up-regulation	Activity	CASP3	hsa836
	Down-regulation	Expression	CDK1	hsa983
	Down-regulation	Expression	CDK2	hsa1017
	Down-regulation	Expression	CDK4	hsa1019
	Down-regulation	Expression	CDK6	hsa1021
	Up-regulation	Expression	H2AX	hsa3014
In Vitro Model	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
In Vivo Model	1×10⁶ human MDA-MB-231 HMTL.6 cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice (40 µl/mouse in 50% matrigel, n = 6).
Result	Our data indicate that [10]-gingerol has potential to be used as a neoadjuvant or in combined therapy with doxorubicin, to improve its anticancer activity.